Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VU0364770 (VU 0364770) 是一种选择性mGlu4正变构调节剂,对 mGlu5 具有拮抗活性,对 mGlu6 具有正变构调节活性。它还对 MAO 具有活性,对人 MAO-A 和 MAO-B 的 Ki 值分别为8.5 和 0.72 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 498 | 现货 | ||
10 mg | ¥ 751 | 现货 | ||
25 mg | ¥ 919 | 现货 | ||
50 mg | ¥ 1,697 | 现货 | ||
100 mg | ¥ 2,708 | 现货 | ||
200 mg | ¥ 3,523 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 848 | 现货 |
产品描述 | VU0364770 (VU 0364770)(EC50=1.1 μM), a positive allosteric modulator(PAM) of mGlu4, shows insignificant activity at 68 other receptors, including other mGlu subtypes. |
靶点活性 | mGlu4:1.1 μM(EC50) |
体外活性 | VU0364770 is a potent and effective positive allosteric modulator of mGlu4. VU0346770 exhibits a potency of 1.1 ± 0.2 μM at human mGlu4 in the presence of an EC20 concentration of glutamate and shifts the glutamate concentration-response curve 31.4 ± 4.0-fold to the left. VU0364770 exhibits a potency of 290 ± 80 nM at rat mGlu4 and induces an 18.1 ± 1.7-fold left shift of the glutamate concentration-response curve. [1] |
体内活性 | VU0364770 shows efficacy alone or when administered in combination with l-DOPA or an adenosine 2A (A2A) receptor antagonist preladenant currently in clinical development. When administered alone, VU0364770 exhibits efficacy in reversing haloperidol-induced catalepsy, forelimb asymmetry-induced by unilateral 6-hydroxydopamine (6-OHDA) lesions of the median forebrain bundle, and attentional deficits induced by bilateral 6-OHDA nigrostriatal lesions in rats. In addition, VU0364770 enhances the efficacy of preladenant to reverse haloperidol-induced catalepsy when given in combination. The effects of VU0364770 to reverse forelimb asymmetry are also potentiated when the compound is coadministered with an inactive dose of l-DOPA, suggesting that mGlu4 positive allosteric modulator may provide l-DOPA-sparing activity. [1] |
激酶实验 | The effects of VU0364770 on rat mGlu1 and mGlu5 are assessed by using calcium mobilization and measuring the glutamate concentration-response relationship in the presence and absence of 10 μM VU0364770. Using a double-addition protocol, VU0364770 is added to the cells, followed 2.5 min later by a full concentration-response of glutamate. Shifts of the concentration-response relationship are used to assess potential potentiator (left shift of more than 2-fold) or antagonist (right shift of more than 2-fold or depression of the maximum response by at least 75%) activity of VU0364770. Compounds are further assessed for mGlu5 antagonist activity by performing a full concentration-response curve, starting at 30 μM and serially diluted it by using 1:3 dilutions, in the presence of an EC80 concentration of glutamate[1]. |
别名 | VU 0364770 |
分子量 | 232.67 |
分子式 | C12H9ClN2O |
CAS No. | 61350-00-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 23.3 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.2979 mL | 21.4897 mL | 42.9793 mL | 107.4483 mL |
5 mM | 0.8596 mL | 4.2979 mL | 8.5959 mL | 21.4897 mL | |
10 mM | 0.4298 mL | 2.149 mL | 4.2979 mL | 10.7448 mL | |
20 mM | 0.2149 mL | 1.0745 mL | 2.149 mL | 5.3724 mL | |
50 mM | 0.086 mL | 0.4298 mL | 0.8596 mL | 2.149 mL | |
100 mM | 0.043 mL | 0.2149 mL | 0.4298 mL | 1.0745 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
VU0364770 61350-00-3 Neuroscience GluR inhibit Metabotropic glutamate receptors VU-0364770 Inhibitor VU 0364770 mGluR inhibitor